-
ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with One or More Prior Anti-HER2-Based RegimensDaiichi Sankyo2021-10-04 08:46:17ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast
-
Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer with Actionable Genomic AlterationsDaiichi Sankyo2021-09-20 13:45:17Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer
-
ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2021-09-20 13:40:42ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic
-
ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-09-20 13:36:34ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in
-
ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 TrialDaiichi Sankyo2021-09-20 13:34:15ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced
-
DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid CancersDaiichi Sankyo2021-09-20 13:29:26DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers
-
DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-09-16 13:19:50DESTINY-Gastric06 Phase 2 Trial of ENHERTU® Initiated in China in Patients with HER2 Positive Advanced Gastric
-
Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO CongressDaiichi Sankyo2021-09-07 10:01:35Daiichi Sankyo Advances Leadership in Oncology with Potentially Practice Changing Data at 2021 ESMO Congress
-
ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-08-09 10:47:51ENHERTU® Significantly Improved Progression-Free Survival in DESTINY-Breast03 Head-to-Head Trial Versus
-
DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced Gastric CancerDaiichi Sankyo2021-07-08 09:52:59DESTINY-Gastric04 Head-to-Head Phase 3 Trial of ENHERTU® Initiated in Patients with HER2 Positive Advanced
